Trials
1 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Thyroid Eye Disease
- Main trialPhase 3
- “A multicenter clinical study to evaluate the efficacy and safety of IBI311 in subjects with inactive thyroid eye disease. The study consists of two parts, with a maximum duration of approximately 64 weeks.”In the company’s words, NCT07113262 on ClinicalTrials.gov
Other drugs for Thyroid Eye Disease
- MHB018AMinghui Pharmaceutical (Hangzhou) Ltd · Phase 3
- ZL-1109Zai Lab (Shanghai) Co., Ltd. · Phase 3
- KHN939Beijing Kanghong Biological Medicine Co., Ltd. · Phase 3
- LinsitinibSling Therapeutics, Inc. · Astellas · Phase 3
- TeprotumumabAmgen · Phase 3
- VRDN-003Viridian Therapeutics, Inc. · Phase 3
Coming up1
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2026 | A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease | |
| Phase 3Completed | 23 Sep 2025 | A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease | |
| Phase 2/3Completed | 20 Dec 2023 | A Study of IBI311 in Subjects With Active Thyroid Eye Disease | |
| Phase 2Completed | 9 Jan 2025 | A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease | |
| Phase 1Completed | 23 Nov 2022 | A Study of IBI311 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026